|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.640 USD | -1.89% |
|
+8.66% | +81.09% |
| 08-03 | Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder | MT |
| 07-29 | TD Cowen Initiates Opus Genetics at Buy | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- IRD Stock
- Consensus Opus Genetics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
